(VIANEWS) – Another day of trading has ended and here’s today’s list of stocks that have had significant trading activity in the US session.

The three biggest winners today are PAVmed, PAVmed, and Nikola.

The three biggest losers today are Canopy Growth, Aurora Cannabis, and Tilray.

Winners today

1. PAVmed (PAVMW) – 105.67%

NASDAQ ended the session with PAVmed jumping 105.67% to $0.03 on Monday, after five consecutive sessions in a row of losses. NASDAQ rose 0.01% to $13,710.24, following the last session’s downward trend on what was a somewhat positive trend exchanging session today.

More news about PAVmed.

2. PAVmed (PAVMZ) – 35.69%

NASDAQ ended the session with PAVmed jumping 35.69% to $0.16 on Monday while NASDAQ jumped 0.01% to $13,710.24.

Yearly Top and Bottom Value

PAVmed’s stock is valued at $0.16 at 17:32 EST, below its 52-week high of $0.17 and way above its 52-week low of $0.12.

More news about PAVmed.

3. Nikola (NKLA) – 32.76%

Nikola Corporation operates as a technology innovator and integrator that develops energy and transportation solutions. It operates through two business units, Truck and Energy. The Truck business unit develops and commercializes battery electric vehicles (BEV) and hydrogen fuel cell electric vehicles (FCEV) to the trucking sector. The Energy business unit develops and constructs a network of hydrogen fueling stations; and offers BEV charging solutions for its FCEV and BEV customers, as well as other third-party customers. The company also assembles, integrates, and commissions its vehicles in collaboration with its business partners and suppliers. Nikola Corporation founded in 2015 and is headquartered in Phoenix, Arizona.

NASDAQ ended the session with Nikola rising 32.76% to $1.58 on Monday, after two successive sessions in a row of gains. NASDAQ jumped 0.01% to $13,710.24, following the last session’s downward trend on what was a somewhat up trend exchanging session today.

: nikola names mary chan as coo, and stock adds to gainsShares of Nikola Corp. gained 0.8% in premarket trading Monday, adding to the recent sharp gains, after the electric vehicle maker said it named Mary Chan as its chief operating officer, effective Oct. 9. , Her expertise will be a tremendous asset to the Nikola team. The stock has soared 36.8% over the past two sessions, fueled by the company saying it expects has advanced 15.9% this year.

Shares of EV maker nikola surge 25% as new operating chief is tappedShares of Nikola Corp. charged higher Monday, adding to the recent sharp gains, after the electric-vehicle maker named Mary Chan as its new chief operating officer, effective Oct. 9.

Earnings Per Share

As for profitability, Nikola has a trailing twelve months EPS of $-1.98.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -132.55%.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, Nikola’s stock is considered to be oversold (<=20).

Earnings Before Interest, Taxes, Depreciation, and Amortization

Nikola’s EBITDA is 22.24.

Moving Average

Nikola’s value is way under its 50-day moving average of $1.86 and way under its 200-day moving average of $1.82.

More news about Nikola.

4. Meten EdtechX Education Group Ltd. (METXW) – 19.08%

NASDAQ ended the session with Meten EdtechX Education Group Ltd. rising 19.08% to $0.02 on Monday, after five successive sessions in a row of losses. NASDAQ jumped 0.01% to $13,710.24, following the last session’s downward trend on what was a somewhat bullish trend trading session today.

Yearly Top and Bottom Value

Meten EdtechX Education Group Ltd.’s stock is valued at $0.02 at 17:32 EST, way above its 52-week high of $0.02.

More news about Meten EdtechX Education Group Ltd..

5. NeuroBo Pharmaceuticals (NRBO) – 17.38%

NeuroBo Pharmaceuticals, Inc., a clinical-stage biotechnology company focuses on developing and commercializing novel pharmaceuticals to treat cardiometabolic diseases. It develops DA-1241, a novel G-Protein-Coupled Receptor 119 agonist with development optionality as a standalone and/or combination therapy for both NASH and T2D; and DA-1726, a novel oxyntomodulin analogue functioning as a GLP1R/GCGR dual agonist for the treatment of NASH and obesity. The company also develops ANA001, a proprietary oral niclosamide formulation for the treatment of patients with moderate COVID-19; NB-01 for the treatment of painful diabetic neuropathy; NB-02 to treat the symptoms of cognitive impairment and modify the progression of neurodegenerative diseases associated with the malfunction of tau protein; and Gemcabene for various indications, including COVID-19 in combination with ANA001. NeuroBo Pharmaceuticals, Inc. was incorporated in 2014 and is headquartered in Boston, Massachusetts.

NASDAQ ended the session with NeuroBo Pharmaceuticals rising 17.38% to $0.54 on Monday while NASDAQ rose 0.01% to $13,710.24.

Earnings Per Share

As for profitability, NeuroBo Pharmaceuticals has a trailing twelve months EPS of $-10.6.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -65.4%.

Yearly Top and Bottom Value

NeuroBo Pharmaceuticals’s stock is valued at $0.54 at 17:32 EST, way under its 52-week high of $25.83 and way higher than its 52-week low of $0.36.

Growth Estimates Quarters

The company’s growth estimates for the current quarter and the next is 97.7% and 93.4%, respectively.

Volume

Today’s last reported volume for NeuroBo Pharmaceuticals is 341862 which is 11.38% below its average volume of 385798.

Moving Average

NeuroBo Pharmaceuticals’s value is above its 50-day moving average of $0.51 and way below its 200-day moving average of $0.70.

More news about NeuroBo Pharmaceuticals.

6. Aspen Group (ASPU) – 12.04%

Aspen Group, Inc., an education technology company, provides online higher education services in the United States. The company offers baccalaureate, master's, and doctoral degree programs in nursing and health sciences, business and technology, arts and sciences, and education fields through Aspen University and United States University. As of April 30, 2022, it had 13,334 degree-seeking students enrolled. Aspen Group, Inc. was founded in 1987 and is based in New York, New York.

NASDAQ ended the session with Aspen Group rising 12.04% to $0.14 on Monday while NASDAQ jumped 0.01% to $13,710.24.

Earnings Per Share

As for profitability, Aspen Group has a trailing twelve months EPS of $-0.37.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -24.26%.

Moving Average

Aspen Group’s worth is under its 50-day moving average of $0.15 and way below its 200-day moving average of $0.19.

Volatility

Aspen Group’s last week, last month’s, and last quarter’s current intraday variation average was a positive 4.92%, a negative 0.64%, and a positive 5.74%.

Aspen Group’s highest amplitude of average volatility was 5.63% (last week), 6.52% (last month), and 5.74% (last quarter).

Volume

Today’s last reported volume for Aspen Group is 58446 which is 72.3% above its average volume of 33921.

More news about Aspen Group.

7. Mediaco Holding (MDIA) – 11.33%

MediaCo Holding Inc. owns and operates radio stations in the United States. The company engages in the operation of WQHT-FM and WBLS-FM radio stations in the New York City area. It owns and operates advertising displays, such as bulletins, posters, and digital billboards primarily in Georgia, Alabama, South Carolina, Florida, Kentucky, West Virginia, and Ohio. The company also offers digital advertising and event, which includes sponsorships, ticket sales, licensing, and syndication services. MediaCo Holding Inc. was incorporated in 2019 and is headquartered in New York, New York.

NASDAQ ended the session with Mediaco Holding rising 11.33% to $0.87 on Monday while NASDAQ jumped 0.01% to $13,710.24.

Earnings Per Share

As for profitability, Mediaco Holding has a trailing twelve months EPS of $-0.22.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -17.9%.

Yearly Top and Bottom Value

Mediaco Holding’s stock is valued at $0.87 at 17:32 EST, way below its 52-week high of $2.28 and way higher than its 52-week low of $0.55.

More news about Mediaco Holding.

8. MMTec (MTC) – 10.89%

MMTec, Inc., together with its subsidiaries, develops and deploys platforms that enable financial institutions to engage in securities market transactions and settlements worldwide. The company operates in two segments, Gujia and MM Global. It offers Internet-based securities solutions comprising Securities Dealers Trading System, which supports securities registration and clearing, account management, risk management, trading and execution, and third party access middleware; Private Fund Investment Management System that supports multi-account management, fund valuation, risk management, quantitative trading access, liquidation, and requisition management; and Mobile Transaction Individual Client System and PC Client System for Apple IOS, Android, PC, and Web applications. The company enables its customers to white label its trading interface, as well as select modular functionalities. It serves hedge funds, mutual funds, registered investment advisors, proprietary trading groups, and brokerage firms. MMTec, Inc. was incorporated in 2018 and is headquartered in Sheung Wan, Hong Kong.

NASDAQ ended the session with MMTec jumping 10.89% to $0.50 on Monday while NASDAQ rose 0.01% to $13,710.24.

Earnings Per Share

As for profitability, MMTec has a trailing twelve months EPS of $-1.95.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -49.66%.

Moving Average

MMTec’s worth is way under its 50-day moving average of $0.73 and way under its 200-day moving average of $0.97.

Revenue Growth

Year-on-year quarterly revenue growth grew by 150.5%, now sitting on 1.1M for the twelve trailing months.

More news about MMTec.

9. Groupon (GRPN) – 10.19%

Groupon, Inc., together with its subsidiaries, operates a marketplace that connects consumers to merchants. It operates in two segments, North America and International. The company sells goods or services on behalf of third-party merchants; and first-party goods inventory. It serves customers through its mobile applications and websites. The company was formerly known as ThePoint.com, Inc. and changed its name to Groupon, Inc. in October 2008. Groupon, Inc. was incorporated in 2008 and is headquartered in Chicago, Illinois.

NASDAQ ended the session with Groupon rising 10.19% to $13.02 on Monday while NASDAQ rose 0.01% to $13,710.24.

Earnings Per Share

As for profitability, Groupon has a trailing twelve months EPS of $-5.26.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -309.27%.

Volume

Today’s last reported volume for Groupon is 1297090 which is 5.76% below its average volume of 1376440.

Moving Average

Groupon’s value is way higher than its 50-day moving average of $9.36 and way above its 200-day moving average of $6.81.

Earnings Before Interest, Taxes, Depreciation, and Amortization

Groupon’s EBITDA is 1.

More news about Groupon.

10. NanoVibronix (NAOV) – 8.4%

NanoVibronix, Inc., through its subsidiary, NanoVibronix Ltd., focuses on the manufacture and sale of noninvasive biological response-activating devices that target biofilm prevention, wound healing, and pain therapy. Its product portfolio includes UroShield, an ultrasound-based product to prevent bacterial colonization and biofilm in urinary catheters, enhance antibiotic efficacy, and decrease pain and discomfort associated with urinary catheter use. The company also offers PainShield, a patch-based therapeutic ultrasound technology to treat pain, muscle spasm, and joint contractures; and WoundShield, a patch-based therapeutic ultrasound device intended to facilitate tissue regeneration and wound healing by using ultrasound to increase local capillary perfusion and tissue oxygenation. It sells its products directly to patients, as well as through distributor agreements in the United States, Israel, Europe, Australia, India, and internationally. The company was incorporated in 2003 and is headquartered in Elmsford, New York.

NASDAQ ended the session with NanoVibronix rising 8.4% to $2.84 on Monday while NASDAQ jumped 0.01% to $13,710.24.

Earnings Per Share

As for profitability, NanoVibronix has a trailing twelve months EPS of $-3.67.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -195.7%.

Earnings Before Interest, Taxes, Depreciation, and Amortization

NanoVibronix’s EBITDA is 19.85.

More news about NanoVibronix.

Losers Today

1. Canopy Growth (CGC) – -15.55%

Canopy Growth Corporation, together with its subsidiaries, engages in the production, distribution, and sale of cannabis and hemp-based products for recreational and medical purposes primarily in Canada, the United States, and Germany. It operates through two segments, Global Cannabis and Other Consumer Products. The company's products include dried cannabis flower, extracts and concentrates, beverages, gummies, and vapes. It offers its products under the Tweed, 7ACRES, 7ACRES Craft Collective, DOJA, Ace Valley, Quatreau, Deep Space, First + Free, Surity Pro, Spectrum Therapeutics, Vert, Tokyo Smoke, Twd, Martha Stewart CBD, DNA Genetics, BioSteel, Storz & Bickel, This Works, HiWay, Simple Stash, Whisl, and Truverra brands. The company was formerly known as Tweed Marijuana Inc. and changed its name to Canopy Growth Corporation in September 2015. Canopy Growth Corporation was incorporated in 2009 and is headquartered in Smiths Falls, Canada.

NASDAQ ended the session with Canopy Growth dropping 15.55% to $1.14 on Monday while NASDAQ rose 0.01% to $13,710.24.

Earnings Per Share

As for profitability, Canopy Growth has a trailing twelve months EPS of $-1.63.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -99.56%.

Revenue Growth

Year-on-year quarterly revenue growth grew by 2.6%, now sitting on 405.71M for the twelve trailing months.

Earnings Before Interest, Taxes, Depreciation, and Amortization

Canopy Growth’s EBITDA is 1.84.

More news about Canopy Growth.

2. Aurora Cannabis (ACB) – -12.39%

Aurora Cannabis Inc., together with its subsidiaries, produces, distributes, and sells cannabis and cannabis-derivative products in Canada and internationally. It operates through three segments: Canadian Cannabis, European Cannabis, and Plant Propagation. The company produces, distributes, and sells medical and consumer cannabis products in Canada. It is also involved in the distribution of wholesale medical cannabis in the European Union (EU); distribution of wholesale medical cannabis in various international markets, including Australia, the Caribbean, South America, and Israel; supply of propagated vegetables and ornamental plants in North America; and distribution and sale of hemp-derived cannabidiol (CBD) products. In addition, the company cultivates and sells dried cannabis, cannabis oils, capsules, edible cannabis, cannabis extracts, and soft gels, which are ingested in various ways, including smoking, vaporizing, and consumption in the form of oil, capsules, edibles, and extracts; and provides dried flowers, vapes, dried milled strains, strain-specific extracts, strain specific cannabis oils, and concentrates. Further, it offers recreational cannabis products, such as flowers, vapes, ingestibles, concentrates, extracts, and CBD products; and patient counseling and outreach services. The company's adult-use brand portfolio includes Aurora Drift, San Rafael '71, Daily Special, Whistler, Being, and Greybeard, as well as CBD brands, Reliva and KG7; and medical cannabis brands include MedReleaf, CanniMed, Aurora, Whistler Medical Marijuana Co, Pedanios, Bidiol, and CraftPlant. Aurora Cannabis Inc. is headquartered in Leduc, Canada.

NYSE ended the session with Aurora Cannabis dropping 12.39% to $0.86 on Monday, after four successive sessions in a row of gains. NYSE fell 0.13% to $15,952.52, following the last session’s downward trend on what was a somewhat down trend exchanging session today.

Earnings Per Share

As for profitability, Aurora Cannabis has a trailing twelve months EPS of $-6.81.

Volume

Today’s last reported volume for Aurora Cannabis is 34709100 which is 108.06% above its average volume of 16681600.

Volatility

Aurora Cannabis’s last week, last month’s, and last quarter’s current intraday variation average was a negative 3.08%, a positive 3.87%, and a positive 4.61%.

Aurora Cannabis’s highest amplitude of average volatility was 10.26% (last week), 8.62% (last month), and 4.61% (last quarter).

More news about Aurora Cannabis.

3. Tilray (TLRY) – -11.77%

Tilray Brands, Inc. engages in the research, cultivation, processing, and distribution of medical cannabis products in Canada, the United States, Europe, Australia, New Zealand, Latin America, and internationally. The company operates through four segments: Cannabis Business, Distribution Business, Beverage Alcohol Business, and Wellness Business. It also offers medical and adult-use cannabis products; purchases and resells pharmaceutical and wellness products; and produces, markets, sells, and distributes beverage alcohol products, and hemp-based food and other wellness products. In addition, the company offers its products under the Tilray, Aphria, Broken Coast, Symbios, B!NGO, The Batch, Dubon, Good Supply, Solei, Chowie Wowie, Canaca, RIFF, SweetWater, Breckenridge Distillery, Alpine Beer Company, and Green Flash brands. It sells its products to retailers, wholesalers, patients, physicians, hospitals, pharmacies, researchers, and governments, as well as direct to consumers. The company was formerly known as Tilray, Inc. and changed its name to Tilray Brands, Inc. in January 2022. Tilray Brands, Inc. is headquartered in Leamington, Canada.

NASDAQ ended the session with Tilray sliding 11.77% to $2.59 on Monday, following the last session’s downward trend. NASDAQ jumped 0.01% to $13,710.24, following the last session’s downward trend on what was a somewhat bullish trend exchanging session today.

Earnings Per Share

As for profitability, Tilray has a trailing twelve months EPS of $-2.34.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -37.14%.

Growth Estimates Quarters

The company’s growth estimates for the current quarter and the next is 61.5% and 54.5%, respectively.

More news about Tilray.

4. Rumble (RUM) – -11.19%

Rumble Inc. operates video sharing platforms in the United States, Canada, and internationally. The company operates rumble.com, a platform where users can subscribe to channels to stay in touch with creators, and access video on-demand (VOD) and live content streamed by creators. It also operates locals.com, a subscription platform for creators and subscribers to engage through VOD, podcasts, live chat, polls, and community discussions; and Rumble Advertising Center (RAC), an online advertising management exchange. The company was founded in 2013 and is headquartered in Longboat Key, Florida.

NASDAQ ended the session with Rumble sliding 11.19% to $6.03 on Monday while NASDAQ rose 0.01% to $13,710.24.

Earnings Per Share

As for profitability, Rumble has a trailing twelve months EPS of $-0.28.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -35.81%.

More news about Rumble.

5. Phio Pharmaceuticals Corp. (PHIO) – -10.3%

Phio Pharmaceuticals Corp. develops immuno-oncology therapeutics in the United States. It offers INTASYL therapeutic platform focuses on targeting tumor and immune cells by regulating genes of the immune system. The company develops PH-762 that activates immune cells to recognize and kill cancer cells by reducing the expression of the checkpoint protein PD-1 for immunotherapy in adoptive cell transfer (ACT); PH-894 that silences the epigenetic protein BRD4, which is an intracellular regulator of gene expression for use in ACT; and PH-804 that targets the suppressive immune receptor TIGIT, which is a checkpoint protein present on T cells and natural killer cells for use in ACT. It has collaborations with AgonOx Inc. on clinical development of novel T cell-based cancer immunotherapies. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Phio Pharmaceuticals Corp. in November 2018. Phio Pharmaceuticals Corp. was incorporated in 2011 and is headquartered in Marlborough, Massachusetts.

NASDAQ ended the session with Phio Pharmaceuticals Corp. sliding 10.3% to $1.48 on Monday, after four sequential sessions in a row of losses. NASDAQ rose 0.01% to $13,710.24, following the last session’s downward trend on what was a somewhat bullish trend exchanging session today.

Earnings Per Share

As for profitability, Phio Pharmaceuticals Corp. has a trailing twelve months EPS of $-9.28.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -92.6%.

Earnings Before Interest, Taxes, Depreciation, and Amortization

Phio Pharmaceuticals Corp.’s EBITDA is 172.2.

Moving Average

Phio Pharmaceuticals Corp.’s value is way below its 50-day moving average of $2.44 and way under its 200-day moving average of $4.21.

Volume

Today’s last reported volume for Phio Pharmaceuticals Corp. is 53765 which is 80.68% above its average volume of 29756.

More news about Phio Pharmaceuticals Corp..

6. Wayfair (W) – -8.85%

Wayfair Inc. engages in the e-commerce business in the United States and internationally. The company provides approximately fourty million products for the home sector under various brands. It offers online selections of furniture, décor, housewares, and home improvement products through its sites, including Wayfair, Joss & Main, AllModern, Birch Lane, Perigold, and Wayfair Professional. The company was founded in 2002 and is headquartered in Boston, Massachusetts.

NYSE ended the session with Wayfair falling 8.85% to $64.72 on Monday, after five successive sessions in a row of losses. NYSE fell 0.13% to $15,952.52, following the last session’s downward trend on what was a somewhat down trend exchanging session today.

Earnings Per Share

As for profitability, Wayfair has a trailing twelve months EPS of $-9.45.

Growth Estimates Quarters

The company’s growth estimates for the ongoing quarter and the next is 76.8% and 80.1%, respectively.

More news about Wayfair.

7. Moderna (MRNA) – -8.59%

Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella-zoster virus, and human immunodeficiency virus vaccines; and public health vaccines consists of Zika and Nipah vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; localized regenerative, systemic intracellular, and inhaled pulmonary therapeutics. It has strategic alliances and collaborations with AstraZeneca; Merck; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Chiesi Farmaceutici S.p.A.; Metagenomi, Inc.; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

NASDAQ ended the session with Moderna falling 8.59% to $104.75 on Monday while NASDAQ jumped 0.01% to $13,710.24.

Earnings Per Share

As for profitability, Moderna has a trailing twelve months EPS of $2.92.

PE Ratio

Moderna has a trailing twelve months price to earnings ratio of 35.87. Meaning, the purchaser of the share is investing $35.87 for every dollar of annual earnings.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 6.91%.

Volatility

Moderna’s last week, last month’s, and last quarter’s current intraday variation average was 2.03%, 0.66%, and 2.05%.

Moderna’s highest amplitude of average volatility was 2.30% (last week), 2.17% (last month), and 2.05% (last quarter).

More news about Moderna.

8. Ebix (EBIX) – -8.48%

Ebix, Inc., together with its subsidiaries, provides on-demand infrastructure software exchanges and e-commerce services to the insurance, financial, travel, cash remittance, and healthcare industries in the United States and internationally. The company develops and deploys insurance and reinsurance exchanges on an on-demand basis using software-as-a-service (SaaS) enterprise solutions in the areas of customer relationship management, front-end and back-end systems, and outsourced administrative and risk compliance solutions. Its EbixCash exchange related products and services include gift cards; travel exchanges services; money transfer services; foreign exchange and outward remittance services; consumer payment services; and on-demand technology to various providers in the areas of lending, wealth and asset management, and travel. The company's insurance exchanges related products and services include SaaS platform and related services; licensing of software; and professional services comprising setup, customization, training, or consulting. Its risk compliance services cover certificates of insurance creation and tracking; consulting services, such as project management, integration, development, and testing; and business process outsourcing services, including domain intensive project management, system consulting services, and claims adjudication/settlement services. The company was formerly known as Delphi Systems, Inc. and changed its name to Ebix, Inc. in December 2003. Ebix, Inc. was founded in 1976 and is headquartered in Johns Creek, Georgia.

NASDAQ ended the session with Ebix dropping 8.48% to $13.11 on Monday while NASDAQ rose 0.01% to $13,710.24.

Earnings Per Share

As for profitability, Ebix has a trailing twelve months EPS of $1.09.

PE Ratio

Ebix has a trailing twelve months price to earnings ratio of 12.03. Meaning, the purchaser of the share is investing $12.03 for every dollar of annual earnings.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 4.64%.

Revenue Growth

Year-on-year quarterly revenue growth declined by 52.8%, now sitting on 874.3M for the twelve trailing months.

Sales Growth

Ebix’s sales growth is negative 40% for the ongoing quarter and negative 49.3% for the next.

Volatility

Ebix’s last week, last month’s, and last quarter’s current intraday variation average was a negative 1.96%, a positive 0.15%, and a positive 4.96%.

Ebix’s highest amplitude of average volatility was 2.46% (last week), 2.79% (last month), and 4.96% (last quarter).

More news about Ebix.

9. Gap (GPS) – -8.21%

The Gap, Inc. operates as an apparel retail company. The company offers apparel, accessories, and personal care products for men, women, and children under the Old Navy, Gap, Banana Republic, and Athleta brands. Its products include denim and khakis; eyewear, jewelry, shoes, handbags, and fragrances; and fitness and lifestyle products for use in yoga, training, sports, travel, and everyday activities for women and girls. The company offers its products through company-operated stores, franchise stores, websites, and third-party arrangements. It has franchise agreements to operate Old Navy, Gap, Banana Republic, and Athleta stores and websites in Asia, Europe, Latin America, the Middle East, and Africa. The company also provides its products through e-commerce sites. The Gap, Inc. was incorporated in 1969 and is headquartered in San Francisco, California.

NYSE ended the session with Gap dropping 8.21% to $10.28 on Monday while NYSE slid 0.13% to $15,952.52.

Earnings Per Share

As for profitability, Gap has a trailing twelve months EPS of $0.29.

PE Ratio

Gap has a trailing twelve months price to earnings ratio of 35.45. Meaning, the purchaser of the share is investing $35.45 for every dollar of annual earnings.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 4.73%.

Dividend Yield

According to Morningstar, Inc., the next dividend payment is on Oct 2, 2023, the estimated forward annual dividend rate is 0.6 and the estimated forward annual dividend yield is 5.51%.

Earnings Before Interest, Taxes, Depreciation, and Amortization

Gap’s EBITDA is 0.56.

Revenue Growth

Year-on-year quarterly revenue growth declined by 8%, now sitting on 15.11B for the twelve trailing months.

More news about Gap.

10. FibroGen (FGEN) – -7.76%

FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, and Duchenne muscular dystrophy; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.

NASDAQ ended the session with FibroGen sliding 7.76% to $0.80 on Monday, after three consecutive sessions in a row of losses. NASDAQ rose 0.01% to $13,710.24, following the last session’s downward trend on what was a somewhat bullish trend exchanging session today.

Earnings Per Share

As for profitability, FibroGen has a trailing twelve months EPS of $-3.18.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -1015.79%.

More news about FibroGen.

Stay up to date with our winners and losers daily report